Rapport pursues precision neuromedicine in an effort to give patients better alternatives to current treatments for neurological diseases, which often come with reduced efficacy and side effects that lead to suboptimal dosing, noncompliance, and discontinuation. By more precisely targeting the neural circuits and cell types where diseases originate, Rapport's approach has the potential to reduce the unwanted drug-target interactions that lead to these issues.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
08/23/23	$150,000,000	Series B	ARCH Venture Partners Cormorant Asset Management Fidelity Management & Research Company Goldman Sachs Asset Management Johnson & Johnson Innovation Logos Capital Perceptive Advisors Sofinnova Ventures Surveyor Capital T. Rowe Price Associates Third Rock Ventures	undisclosed